Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus FLURANDRENOLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus FLURANDRENOLIDE.
ARAZLO vs FLURANDRENOLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Clinical Note
moderateFlurandrenolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin."
Clinical Note
moderateFlurandrenolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin."
Clinical Note
moderateFlurandrenolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Flurandrenolide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin."